All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Clinical comparison

Sincalide (Kinevac) vs Vosoritide (Voxzogo)

An educational, source-based comparison of Sincalide (Kinevac) and Vosoritide (Voxzogo) — how each peptide works, what it's researched for, and what to know before going deeper.

CCK Analog · Diagnostics
Sincalide (Kinevac)

Synthetic C-terminal octapeptide of cholecystokinin for gallbladder imaging.

Mechanism

Synthetic CCK-8 that binds CCK-A receptors on gallbladder smooth muscle, triggering contraction; used to assess gallbladder ejection fraction in cholescintigraphy.

Research areas
  • Gallbladder ejection fraction (HIDA scan)
  • Pancreatic secretion testing
  • Small bowel transit imaging
Considerations
  • FDA-approved.
  • Abdominal cramping, nausea, diarrhea common; contraindicated in suspected gallstone obstruction.
Full Sincalide (Kinevac) profile →
CNP Analog · Skeletal Growth
Vosoritide (Voxzogo)

C-type natriuretic peptide analog for achondroplasia.

Mechanism

Modified C-type natriuretic peptide (CNP) analog that binds NPR-B, antagonizing overactive FGFR3 signaling in the growth plate to increase endochondral bone growth in children with achondroplasia.

Research areas
  • Achondroplasia in children ≥5 years (now ≥4 months)
Considerations
  • FDA-approved.
  • Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Full Vosoritide (Voxzogo) profile →

Sincalide (Kinevac) vs Vosoritide (Voxzogo) — Key differences

  • Class: Sincalide (Kinevac) is classified as CCK Analog · Diagnostics, while Vosoritide (Voxzogo) is CNP Analog · Skeletal Growth.
  • Primary research focus: Sincalide (Kinevac)gallbladder ejection fraction (hida scan); Vosoritide (Voxzogo)achondroplasia in children ≥5 years (now ≥4 months).
  • Tag: FDA-Approved · Diagnostics vs FDA-Approved · Genetic.

Related comparisons